Bimekizumab Versus Ustekinumab Efficacy Across Subgroups of Patients With Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial. J of Skin 2021, 5 (1), s16. https://doi.org/10.25251/skin.5.supp.16.